Oracle Introduces New Version of Oracle Health Sciences Translational Research Center Platform
Oracle Health Sciences announced the availability of the latest version of Oracle Health Sciences Translational Research Center, a platform that enables secondary use of electronic health records, administrative data and omics data to help accelerate biomarker identification for drug discovery, clinical development and translational research.
The new release expands Oracle Health Sciences Translational Research Center’s patient-centric query capabilities, enabling users to create searches that span phenotype and genotype attributes to quickly identify targeted patient populations. For example, users can now set search parameters for a patient’s demographics, cost and treatment timeline, combined with a variety of specific genetic variants in a single search to unlock new insights and advance personalized medicine initiatives. Users can also create gene-centric searches, which enable researchers to retrieve and further analyze all available omics data for particular gene sets of interest within a large data set.
This new release integrates genomic visualization tools that provide holistic views of multiple omics data modalities to enable systems biology-based approaches essential for understanding disease.
In addition to Oracle Health Sciences Translational Research Center’s existing adapters for loading customer-generated molecular profiling data – as well as public domain data from sources such as Ensembl, The Cancer Genome Atlas, 1000 Genomes and Pathway Commons – the new release extends the omics databank by providing pre-built adapters for RNA sequencing (RNA-seq) and SIFT/Polyphen data sets, further speeding time-to-value for end users. Running on Oracle Exadata Database Machine, Oracle Health Sciences Translational Research Center provides the high performance and extreme scalability required to deliver real-time query response against extremely large whole genome data sets. Oracle Health Sciences Translational Research Center can be deployed on-premise, in the HIPAA-certified Oracle Health Sciences Cloud, or in a hybrid model that leverages both to provide organizations with maximum flexibility in their deployment options.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
Phase III Trial Data Show Subcutaneous Pembrolizumab as Noninferior to IV Keytruda
March 31st 2025Subcutaneous administration of pembrolizumab with chemotherapy demonstrated a nearly 50% reduction in patient chair and treatment room time while maintaining efficacy and safety endpoints compared to intravenous Keytruda.
Phase II ALPACA Trial Shows Lepodisiran Produces Significant, Sustained Lipoprotein(a) Reductions
March 31st 2025Eli Lilly’s lepodisiran, an investigational siRNA therapy, achieved significant and durable reductions in lipoprotein(a) levels, a major genetic risk factor for cardiovascular disease.
